Strong Q3 results - Biosimilars remain the key
05/11/25 -"Fresenius delivered strong Q3 results, driven by broad-based growth across Kabi and Helios, with improving margins despite some challenges. Kabi’s Biopharma remained the key growth engine, ..."
Pages
58
Language
English
Published on
05/11/25
You may also be interested by these reports :
05/11/25
Demant’s Q3 organic sales slightly exceeded expectations, driven by growth in hearing care and hearing aids, though partially offset by weakness in ...
05/11/25
Fresenius delivered strong Q3 results, driven by broad-based growth across Kabi and Helios, with improving margins despite some challenges. Kabi’s ...
05/11/25
Qiagen reported better-than-expected Q3 results, with healthy growth across segments supporting the top line. Profitability also improved, prompting ...
04/11/25
bioMerieux’s Q3 sales fell short of expectations. Organic sales growth was primarily driven by a robust performance in Industrial Applications. ...